ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MGNX), a biopharmaceutical company focused on developing, ...
MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...
MacroGenics (NASDAQ: MGNX) Q3 2024 Earnings Call Nov 05, 2024, 4:30 p.m. ET ...
MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Investment analysts at B. Riley issued their FY2024 EPS estimates for shares ...
Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have ...
Hosted on MSN6d
JMP Securities Downgrades MacroGenics (MGNX)Fintel reports that on November 7, 2024, JMP Securities downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Market ...
Macrogenics is positioned at the top for Revenue Growth with a decline of 17.81%, while its peer is at the bottom with a decrease of 59.42%. In terms of Gross Profit, Macrogenics is ahead with $7.97M, ...
Maryland-based MacroGenics, a biopharma focused on discovering, developing, manufacturing and commercializing innovative ...
Good afternoon. We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment. All participants are on a listen-only mode at the moment ...
Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback